Existence of the lymphatic system in the primate corpus luteum

Lymphatic Research and Biology

Volumn 7, Issue 3, 2009, Pages 159-168

  Xu, Fuhua ^a   Stouffer, Richard L ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; COMPLEMENTARY DNA; HYALURONIC ACID; MESSENGER RNA; RECEPTOR PROTEIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS LUTEUM; ENDOTHELIUM CELL; FEMALE; FLUORESCENCE ANALYSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LUTEAL PHASE; LYMPH VESSEL; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM; LYMPHATIC SYSTEM EXAMINATION; LYMPHOID CELL; MACACA; MENSTRUAL CYCLE; NONHUMAN; OVARY FOLLICLE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA; TISSUE STRUCTURE;

ANIMALS; CORPUS LUTEUM; FEMALE; FLUORESCENT DYES; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC SYSTEM; MACACA; MENSTRUAL CYCLE; OVARY; PRIMATES; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3; VESICULAR TRANSPORT PROTEINS; VON WILLEBRAND FACTOR;

EID: 70449476142     PISSN: 15396851     EISSN: None     Source Type: Journal    
DOI: 10.1089/lrb.2009.0009     Document Type: Article

References (63)

1. Brown P. Lymphatic system: Unlocking the drains. Nature 2005;436:456-458.
2. Al-Rawi MA, Mansel RE, Jiang WG. Lymphangiogenesis and its role in cancer. Histol Histopathol 2005;20:283-298.
3. Witte MH, Bernas MJ, Martin CP, Witte CL. Lymphangiogenesis and lymphangiodysplasia: From molecular to clinical lymphology. Microsc Res Tech 2001;55:122-145.
4. Achen MG, McColl BK, Stacker SA. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005;7:121-127.
5. Otrock ZK, Makarem JA, Shamseddine AI. Vascular endothelial growth factor family of ligands and receptors: Review. Blood Cells Mol Dis 2007;38:258-268.
6. Nash AD, Baca M, Wright C, Scotney PD. The biology of vascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther 2006;19:61-69.
7. Ferrara N. Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog Hormone Res 2000; 55:15-35; discussion 35-116
8. Joukov V, Pajusola K, Kaipainen A, et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996;15:290-298.
9. Achen MG, Jeltsch M, Kukk E, et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 1998;95:548-553.
10. Karkkainen MJ, Haiko P, Sainio K, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol 2004;5: 74-80.
11. Ny A, Koch M, Schneider M, et al. A genetic Xenopus laevis tadpole model to study lymphangiogenesis. Nat Med 2005; 11:998-1004.
12. Baldwin ME, Halford MM, Roufail S, et al. Vascular endothelial growth factor D is dispensable for development of the lymphatic system. Mol Cell Biol Mar 2005;25:2441-2449.
13. Goldman J, Le TX, Skobe M, Swartz MA. Overexpression of VEGF-C causes transient lymphatic hyperplasia but not increased lymphangiogenesis in regenerating skin. Circ Res 2005;96:1193-1199.
14. Veikkola T, Jussila L, Makinen T, et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001;20: 1223-1231.
15. Al-Rawi MA, Mansel RE, Jiang WG. Molecular and cellular mechanisms of lymphangiogenesis. Eur J Surg Oncol 2005; 31:117-121.
16. Partanen TA, Arola J, Saaristo A, et al. VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues. FASEB J 2000;14:2087-2096.
17. Makinen T, Jussila L, Veikkola T, et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat Med 2001;7: 199-205.
18. Pytowski B, Goldman J, Persaud K, et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 2005;97:14-21.
19. Morris B, Sass MB. The formation of lymph in the ovary. Proc R Soc B 1966;164:577-591.
20. Andersen D. Lymphatic and blood vessels of the ovary of the sow. Contr Embryol 1926;88:107-124.
21. Otsuki Y, Magari S, Sugimoto O. Fine structure and morphometric analysis of lymphatic capillaries in the developing corpus luteum of the rabbit. Lymphology 1987;20:64-72.
22. Murata K. Fine distribution of lymph vessels within the ovaries. J Tokyo Med College 1976;34:425-437.
23. Czeizel E, Palkovich I. [Study of the interual lymphatic vessels of the ovary by experimental lymph stasis.]. Anatomischer Anzeiger 1962;111:413-425.
24. Ichikawa S, Uchino S, Hirata Y. Lymphatic and blood vasculature of the forming corpus luteum. Lymphology 1987; 20:7383.
25. Lee RT. Lessons from lymph: Flow-guided vessel formation. Circ Res 2003;92:701-703.
26. Yoffey JM. Lymphatic, Lymph and the Lymphomyeloid Complex. London: Academic Press; 1970.
27. Koering MJ. Cyclic changes in ovarian morphology during the menstrual cycle in Macaca mulatta. Am J Anat 1969;126: 73-101.
28. Di Fiore MSH. Atlas of Human Histology. Third Ed. Philadelphia: Lea & Febiger; 1967.
29. van Wagenen G, Simpson ME. Postnatal Development of the Ovary in Homo sapiens and Macaca mulatta. New Haven and London: Yale University Press; 1973.
30. Banerji S, Ni J, Wang SX, et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 1999;144:789-801.
31. Prevo R, Banerji S, Ferguson DJ, Clasper S, Jackson DG. Mouse LYVE-1 is an endocytic receptor for hyaluronan in lymphatic endothelium. J Biol Chem 2001;276:19420-19430.
32. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas. Modern Pathol 2002;15:434-440.
33. Wilting J, Papoutsi M, Christ B, et al. The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. FASEB J 2002;16:1271-1273.
34. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: Podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385-394.
35. Pepper MS, Skobe M. Lymphatic endothelium: Morphological, molecular and functional properties. J Cell Biol 2003; 163:209-213.
36. Mukai K, Rosai J, Burgdorf WH. Localization of factor VIIIrelated antigen in vascular endothelial cells using an immunoperoxidase method. Am J Surg Pathol 1980;4:273-276.
37. Sehested M, Hou-Jensen K. Factor VII related antigen as an endothelial cell marker in benign and malignant diseases. Virchows Archiv A, Pathol Anat Histol 1981;391:217-225.
38. Christenson LK, Stouffer RL. Proliferation of microvascular endothelial cells in the primate corpus luteum during the menstrual cycle and simulated early pregnancy. Endocrinology 1996;137:367-374.
39. Andersen DH. Lymphatics and blood-vessels of the ovary of the sow. Contrib Embryol 1926:88:107-124.
40. Burr JH, Jr., Davies JI. The vascular system of the rabbit ovary and its relationship to ovulation. Anatom Rec 1951;111:273-297.
41. Hazzard TM, Christenson LK, Stouffer RL. Changes in expression of vascular endothelial growth factor and angiopoietin-1 and -2 in the macaque corpus luteum during the menstrual cycle. Mol Hum Reprod 2000;6:993-998.
42. Tesone M, Stouffer RL, Borman SM, Hennebold JD, Molskness TA. Vascular endothelial growth factor (VEGF) production by the monkey corpus luteum during the menstrual cycle: Isoform-selective messenger RNA expression in vivo and hypoxia-regulated protein secretion in vitro. Biol Reprod 2005;73:927-934.
43. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997;277:48-50.
44. Brown HM, Dunning KR, Robker RL, Pritchard M, Russell DL. Requirement for ADAMTS-1 in extracellular matrix remodeling during ovarian folliculogenesis and lymphangiogenesis. Dev Biol 2006;300:699-709.
45. Chen H, Chedotal A, He Z, Goodman CS, Tessier-Lavigne M. Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III.[erratum: Neuron 1997;19:559]. Neuron 1997;19:547-559.
46. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci USA 2001;98:12677-12682.
47. Yuan L, Moyon D, Pardanaud L, et al. Abnormal lymphatic vessel development in neuropilin 2 mutant mice. Development 2002;129:4797-4806.
48. Xu F, Hazzard TM, Scheffler LJ, Stouffer RL. Neuropilin-1 and -2 expression in the monkey corpus luteum during the menstrual cycle. Biol Reprod 2002;66:181-182.
49. Hein WR, Shelton JN, Simpson-Morgan MW, Seamark RF, Morris B. Flow and composition of lymph from the ovary and uterus of cows during pregnancy. J Reprod Fertil 1988;83:309-323.
50. Lindner HR, Sass MB, Morris B. Steroids in the ovarian lymph and blood of conscious ewes. J Endocrinol 1964;30: 361-376.
51. Daniel PM, Gale MM, Pratt OE. Hormones and related substances in the lymph leaving four endocrine glands-the testis, ovary, adrenal, and thyroid. Lancet 1963;1:1232-1234.
52. Olofsson B, Jeltsch M, Eriksson U, Alitalo K. Current biology of VEGF-B and VEGF-C. Curr Opin Biotechnol 1999;10:528-535.
53. Vittay P, Bosze P, Gaal M, Laszlo J. Lymph vessel defects in patients with ovarian dysgenesis. Clin Genet 1980;18:387-391.
54. Czeizel E, Palkovich I. [The role of the lymphatic circulation in the pathogenesis of follicular cysts of the ovary.]. Zentralblatt fur Gynakologie 1962;84:418-426.
55. Sundar SS, Zhang H, Brown P, et al. Role of lymphangiogenesis in epithelial ovarian cancer. Br J Cancer 2006;94: 1650-1657.
56. Wolf DP, Thomson JA, Zelinski-Wooten MB, Stouffer RL. In vitro fertilization embryo transfer in nonhuman primates: The technique and its applications. Mol Reprod Dev 1990; 27:261-280.
57. Young KA, Stouffer RL. Gonadotropin and steroid regulation of matrix metalloproteinases and their endogenous tissue inhibitors in the developed corpus luteum of the rhesus monkey during the menstrual cycle. Biol Reprod 2004;70: 244-252.
58. Duffy DM, Stewart DR, Stouffer RL. Titrating luteinizing hormone replacement to sustain the structure and function of the corpus luteum after gonadotropin releasing hormone antagonist treatment in rhesus monkeys. J Clin Endocrinol Metab 1999;84:342-349.
59. Duffy DM, Chaffin CL, Stouffer RL. Expression of estrogen receptor alpha and beta in the rhesus monkey corpus luteum during the menstrual cycle: Regulation by luteinizing hormone and progesterone. Endocrinology 2000;141:1711-1717.
60. Tsoi SC, Zheng J, Xu F, Kay HH. Differential expression of lactate dehydrogenase isozymes (LDH) in human placenta with high expression of LDHA( 4) isozyme in the endothelial cells of pre-eclampsia villi. Placenta 2001;22:317-322.
61. Hazzard TM, Xu F, Stouffer RL. Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys. Biol Reprod 2002;67:1305-1312.
62. Chaffin CL, Stouffer RL, Duffy DM. Gonadotropin and steroid regulation of steroid receptor and aryl hydrocarbon receptor messenger ribonucleic acid in macaque granulosa cells during the periovulatory interval. Endocrinology 1999; 140:4753-4760.
63. Young KA, Hennebold JD, Stouffer RL. Dynamic expression of mRNAs and proteins for matrix metalloproteinases and their tissue inhibitors in the primate corpus luteum during the menstrual cycle. Mol Hum Reprod 2002;8:833-840.